Takeda Pharmaceutical Files 6-K Report

Ticker: TKPHF · Form: 6-K · Filed: Dec 13, 2024 · CIK: 1395064

Takeda Pharmaceutical Co Ltd 6-K Filing Summary
FieldDetail
CompanyTakeda Pharmaceutical Co Ltd (TKPHF)
Form Type6-K
Filed DateDec 13, 2024
Risk Levellow
Pages7
Reading Time8 min
Key Dollar Amounts$10B, $20B
Sentimentneutral

Sentiment: neutral

Topics: reporting, foreign-issuer

TL;DR

Takeda filed a 6-K on 12/13/24, standard reporting for foreign issuers.

AI Summary

Takeda Pharmaceutical Company Limited filed a Form 6-K on December 13, 2024, reporting information as of December 2024. The filing is for a foreign private issuer and indicates Takeda files annual reports under Form 20-F. The company's principal executive offices are located in Tokyo, Japan.

Why It Matters

This filing provides routine updates for Takeda Pharmaceutical, a major global biopharmaceutical company, to the SEC, ensuring transparency for investors.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational news that would indicate a change in risk.

Key Players & Entities

  • Takeda Pharmaceutical Company Limited (company) — Filer
  • 0001395064-24-000172 (other) — Accession Number
  • 20241213 (date) — Filing Date
  • Tokyo, Japan (location) — Principal Executive Offices

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, providing information that the registrant has made or is required to make public pursuant to the laws of its home country or that it has submitted or is required to submit to or will distribute or is required to distribute to its security holders.

What is Takeda Pharmaceutical Company Limited's standard reporting form for annual reports?

Takeda Pharmaceutical Company Limited indicates it files annual reports under cover of Form 20-F.

Where are Takeda Pharmaceutical Company Limited's principal executive offices located?

The principal executive offices of Takeda Pharmaceutical Company Limited are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.

What is the filing date of this specific Form 6-K?

This Form 6-K filing has a conformed period of report and filed as of date of 20241213.

Is Takeda Pharmaceutical Company Limited submitting this Form 6-K in paper format?

The filing does not indicate that Takeda Pharmaceutical Company Limited is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) or Rule 101(b)(7).

Filing Stats: 1,978 words · 8 min read · ~7 pages · Grade level 17.9 · Accepted 2024-12-13 06:07:49

Key Financial Figures

  • $10B — Programs with Peak Revenue Potential of $10B - $20B 1 Poised to Deliver Sustainable
  • $20B — s with Peak Revenue Potential of $10B - $20B 1 Poised to Deliver Sustainable Growth

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date December 13, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller News Release Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B 1 Poised to Deliver Sustainable Growth Expected Phase 3 Data Readouts in 2025 for Oveporexton (TAK-861), Zasocitinib (TAK-279) and Rusfertide (TAK-121) Regulatory Filings for Oveporexton (narcolepsy type 1), Zasocitinib (psoriasis) and Rusfertide (polycythemia vera) on Track for Fiscal Years 2025 - 2026 Five Additional Filings Anticipated in Fiscal Years 2027-2029 Including First Indication Submissions for Mezagitamab (TAK-079), Fazirsiran (TAK-999) and Elritercept (TAK-226) OSAKA, Japan and CAMBRIDGE, Massachusetts, December 13, 2024 – Takeda ( TSE4502NYSETAK ) will host an investor RD Day today beginning at 830 a.m. JST in Tokyo. The meeting will focus on programs in the company's late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. "We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum of our Growth and Launch Products," said Christophe Weber, Takeda chief executive officer. "The first three Phase 3 programs will read out in 2025, initiating a cadence of potential filings across multiple indications over the next several years." Eight Regulatory Filings in FY2025 – FY2029 The late-stage pipeline includes oveporexton (TAK-861), zasocitinib (TAK-279), rusfertide (TAK-121), me

Forward-Looking Statements

Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States competitive pressures and developments changes to applicable laws and regulations, including global health care reforms challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof uncertainty of commercial success for new and existing products manufacturing difficulties or delays fluctuations in interest and currency exchange rates claims or concerns regarding the safety or efficacy of marketed products or product candidates the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business the timing and impact of post-merger integration efforts with acquired companies the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s) and other factors identified in Takeda's most recent Annual Report on Form 20-F and Take

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.